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We investigated whether CD4 gene regulatory sequences might be useful for developing transcriptionally targeted
Moloney murine leukemia virus (Mo-MLV)-based retroviral vectors for gene expression specifically in CD41 cells. We could
modulate Mo-MLV long terminal repeat (LTR) activity by inserting a 438-bp-long fragment containing the murine CD4 silencer
in the LTR of the vector; both b-galactosidase and green fluorescent protein reporter gene activities were strongly
down-regulated in both murine and human CD81 cells, but not in CD41 lymphoid cell lines and freshly isolated lymphocytes
transduced with this vector, compared with the findings using a control vector carrying wild-type LTRs. Titration experiments
on NIH-3T3 cells revealed that inclusion of the CD4 silencer in the LTRs did not reduce the titer of the vectors. These findings
indicate that a cellular silencer can be successfully included in retroviral vectors, where it maintains its transcription-
regulatory function, thus suggesting a novel approach to transcriptional targeting. © 2000 Academic Press
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INTRODUCTION
Retroviral vectors derived from the Moloney murine
leukemia virus (Mo-MLV) are widely used to transfer
genes of interest into a variety of animal and human
cells, both in vitro and in vivo (Verma and Somia, 1997).
Among the many shortcomings that hamper in vivo gene
transfer by retroviral vectors, specificity of gene transfer
and expression are of major concern (Gunzburg and
Salmons, 1996). Retroviral tropism is controlled at differ-
ent levels, including specificity of infection for selected
cell types and transcriptional activity of the viral long
terminal repeat (LTR) in the infected cell. Our group
previously focused on vectors targeting T lymphocytes in
terms of specificity of infection and could show the fea-
sibility of generating both MLV/HIV and MLV/SIV
pseudotypes to selectively target CD41 cells at the level
of virus entry (Indraccolo et al., 1998; Mammano et al.,
1997). As a complementary approach, we evaluated the
possibility of transcriptionally targeting a retroviral vector
to CD4-expressing lymphoid cells by inserting regulatory
sequences from the tightly regulated CD4 gene into the
viral LTR. Engineering the viral LTR with tissue-specific
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Oncology and Surgical Sciences, via Gat-s
r
amelata 64, I-35128 Padova, Italy. Fax: 1139-049-8072854. E-mail:
ndra@ux1.unipd.it.
83therapy.
regulatory sequences is one of the favorite approaches
to transcriptional targeting, in view of the fact that the
LTR drives the expression of the marker/therapeutic
genes in most retroviral vectors, and has been shown to
be successful in many cases (Couture et al., 1994; Fas-
sati et al., 1998; Golemis et al., 1990; Mrochen et al., 1997;
Robinson et al., 1995; Saller et al., 1998; Valerio et al.,
1989; Vile et al., 1995). We focused on the CD4 gene
because detailed information on its regulated expression
was available. Indeed, previous studies identified pro-
moter sequences from the human gene that are neces-
sary and sufficient for tissue-specific expression of a
reporter gene in transient transfection assays (Salmon et
al., 1993); furthermore, a proximal murine CD4 enhancer,
which is indispensable for correct expression of the
transgene in transgenic mice, has also been character-
ized (Boyer et al., 1997; Salmon et al., 1996; Sawada and
Littman, 1991). Finally, recent studies have uncovered a
murine CD4 silencer, located in the first intron of the
gene, which might contribute to the down-regulation of
CD4 expression in CD81 cells and thus lead to the
eneration of single positive CD4 and CD8 cells in the
hymus (Sawada et al., 1994). Our findings show that it is
easible to exploit a cellular silencer from the CD4 gene
o modulate the activity of the viral LTR: since previous
tudies with hybrid LTRs exploited exclusively either tis-
ue-specific promoters or enhancers, this extends the
epertoire of sequences that can be useful for transcrip-
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COLOtional targeting of retroviral vectors. While targeting of
CD41 cells in vitro can be easily achieved at the level of
viral entry, i.e., by immunoselection of the CD41 subset
r by using the above-mentioned pseudotypes, a tran-
criptionally targeted silencer-containing vector could be
seful for gene transfer into hematopoietic stem cells, in
rder to direct expression of the therapeutic gene(s) in
he T lymphoid compartment; furthermore a cellular si-
encer could be exploited in vectors for direct in vivo
ene transfer targeting this cell subset.
RESULTS AND DISCUSSION
eneration of retroviral vectors and transduction
f NIH-3T3 cells
We constructed retroviral vectors carrying these CD4
ene regulatory elements as detailed in Fig. 1 and under
aterials and Methods. Retroviral vector-containing su-
ernatants (SNs) were first used to transduce murine
ibroblast NIH-3T3 cells in order to check for vector
roduction and determine the genomic stability of the
FIG. 1. Schematic representation of the constructs used to produce
Mo-MLV-based vectors by transient transfection. (A) Mo-MLV Gag-Pol
expression plasmid (pgag-polgpt) (Markowitz et al., 1988). (B) A-MLV
Env expression plasmid (Page et al., 1990). (C) b-gal and EGFP trans-
fer vectors containing different CD4 gene regulatory elements. The
Mo-MLV packaging signal (c) is deleted in pgag-polgpt but is present
in each vector genomic-RNA encoding construct; some constructs
carry a longer encapsidation signal (c1), which also comprise some
ag sequences that increase packaging efficiency (Miller and Rosman,
989). p(A), polyadenylation signal; SV, simian virus 40 promoter; neoR,
eomycin phosphotransferase gene; CD4P, human CD4 promoter; E,
urine CD4 proximal enhancer; CD4S, murine CD4 silencer. The gray
ox indicates the Mo-MLV enhancer; the approssimate position of the
iral promoter in the CD4 silencer-carrying vectors is indicated by the
ATA-box. Restriction sites relevant for cloning are indicated: S, SacII;
, MluI; X, XbaI.
84 INDRACectors. Titer was determined by G418 selection, as all
ectors used in this study carried an SV40 promoter-
a
uriven neomycin phosphotransferase gene that allows
rug-mediated selection of vector-transduced cells. Both
he construct containing the human CD4 promoter (pro-
on-CD4P) and the one carrying this sequence linked to
he murine CD4 proximal enhancer (procon-CD4P 1 E)
see Fig. 1) yielded similar virus titers. In three indepen-
ent experiments, 2.2 6 0.9 3 103 and 2.6 6 1.2 3 103
cfu/ml of SN were obtained on average; these figures are
about 10-fold lower than those generated by the retrovi-
ral vector LBSN carrying wild-type LTRs and the one
carrying the CD4 silencer in the LTR (on average 15 6
2.6 3 103 and 22 6 1.5 3 103 cfu/ml, respectively). This
difference may be explained in part by intrinsic genomic
differences in the vectors, such as a longer encapsida-
tion signal (c1) in the LBSN-derived vectors, which de-
rive from LXSN and also comprise some gag sequences
that increase packaging efficiency (Miller and Rosman,
1989), compared to first-generation procon vectors,
which are derived from pBAG (Mrochen et al., 1997;
Saller et al., 1998).
Assessment of promoter conversion and vector
stability in transduced NIH-3T3 cells
To rule out the possibility that cellular sequences in-
cluded in the vectors might affect their genomic stability
and lead to rearrangements, we analyzed genomic DNA
from pools of 50–100 clones of G418-resistant NIH-3T3
cells by either polymerase chain reaction (PCR) or South-
ern blotting techniques. In the case of LBSN-CD4S, pro-
virus integrity and the presence of the silencer in the 59
end LTR were verified by Southern blot analysis; to this
end, genomic DNA of transduced NIH-3T3 cells and of
control transfected 293T cells was digested with either
NheI or KpnI, both of which cleave once in each proviral
LTR, blotted, and hybridized to a neoR probe. The vectors
employed and representative restriction patterns ob-
tained are shown in Fig. 2. In the LBSN-CD4S-trans-
duced NIH-3T3 sample, NheI digestion generated a
band of 8.1 kb, which accounted for the size of a provirus
containing a modified 59 LTR derived from correct dupli-
cation of the 39 LTR. The integrity of the 39 LTR was
etermined by digestion with KpnI, which generated an
xpected band of 8.1 kb. In the producer 293T cells,
btained by transfection of LBSN-CD4S plasmid DNA,
he size of the band obtained after NheI digestion (7.7 kb)
as smaller than that obtained after KpnI digestion (8.1
b), because the CD4 silencer is present only in the 39
TR (Fig. 2). These results indicate correct LTR duplica-
ion and integrity of the viral transcriptional unit in NIH-
T3 cells transduced by the LBSN-CD4S vector. To con-
irm these findings, we designed a PCR approach, based
n amplification of genomic DNA with primers binding to
he U3 region, 59 to the cloning site of the CD4 silencer,
ET AL.nd to the C region of the vector (Fig. 2A), as detailed
nder Materials and Methods. PCR amplification yielded
as posbands of 680 and 1120 bp when DNA from LBSN-CD4S-
transfected and -transduced cells was used as a tem-
plate, respectively (Fig. 2C). This is due to the fact that,
following proviral formation, the CD4 silencer is trans-
posed to the 59 LTR of the vector, where it is inserted in
the U3 region. On the other hand, PCR amplification of
LBSN-transduced cells yielded a band of 680 bp, which
was identical in size to that obtained from LBSN-trans-
fected 293T cells, due to the lack of the CD4 silencer in
FIG. 2. Analysis of proviral DNA in transduced cells. (A) Schematic m
of restriction fragments. The approximate position of the LBSN-for (3
Southern blot analysis of LBSN-CD4S retroviral integration in genomic D
mg/lane) were digested with NheI (lanes 1 and 2) and KpnI (lanes 3–6)
from either LBSN-CD4S-transduced cells (8.1 kb) (lane 2) or LBSN-CD4S
either transfected or transduced with vector LBSN are also shown as
molecular weight marker l HindIII is indicated. (C) PCR analysis of ve
either transfected or transduced with the LBSN and LBSN-CD4S vector
the LBSN and LBSN-CD4S plasmids and water (lanes 6–8) were used
from 293T LBSN-CD4S-transduced cells is indicated with an arrow.
CD4 SILENCER ACTIVITthis vector (Fig. 2C). In the case of the procon-CD4P and
procon-CD4P 1 E vectors, we also verified correct pro-moter conversion in transduced cells by exploiting a PCR
assay which enabled us to distinguish pre- and postcon-
version templates by the size of the PCR product (data
not shown).
Determination of b-galactosidase (b-gal) activity
in lymphoid and nonlymphoid cell lines
To test the activity of the different constructs carrying
the LBSN and LBSN-CD4S retroviral vectors and of the expected size
LBSN-rev (4) primers used for PCR experiments is also shown. (B)
m vector-transduced NIH-3T3 and 293T virus producer cells. DNAs (10
bridized to a neoR probe. The expected bands in NheI-digested DNA
ected cells (7.7 kb) (lane 1) are indicated with arrows. DNAs from cells
trol for the size of the wild-type provirus (7.7 kb) (lanes 5 and 6). The
nsduced cells. PCR was performed on genomic DNA from 293T cells
s 1–4) or control nontransduced 293T cells (lane 5). Ten nanograms of
itive and negative controls for PCR, respectively. The band generated
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8pression. The procon-CD4P and procon-CD4P 1 E vec-
tors expressed very low levels of b-gal activity in NIH-
T3 cells, compared to LBSN (Fig. 3A). This result was
redicted since b-gal is driven by the tissue-specific
uman CD4 promoter in these constructs, and this pro-
oter is not expected to be active in NIH-3T3 cells.
nexpectedly, however, b-gal activity was also weak in
the murine CD41 EL-4 cell line transduced with the
rocon-CD4 vectors, compared to the LBSN vector (Fig.
B). Similar results were obtained in the human CD41,
olt-3, and Jurkat cell lines (data not shown). Thus, the
uman CD4 promoter, at least in this configuration, is
oorly active in the context of a promoter-conversion
etroviral vector, compared to the Mo-MLV promoter. On
he other hand, the LBSN-CD4S vector, carrying the CD4
ilencer in the LTRs, yielded measurable b-gal activity in
ll cell lines tested (Fig. 3 and data not shown); in
articular, b-gal activity was reduced only by 25% in the
CD41 murine EL-4 cell line when compared to the b-gal
activity shown after transduction of the same cells with
the LBSN vector (Fig. 3B). However, the CD4 silencer
strongly down-modulated reporter gene expression in
the CD81 murine CTLL-2 cell line; activity of the LBSN-
FIG. 3. Determination of b-gal activity in vector-transduced G418-sele
C), and mammary tumor TSA-E1 (D) cell lines were transduced with th
eeks; cell lysates were assayed for b-gal expression as described und
as counts per second (cps) per microgram protein in the cell lysates.
endogenous activity). Standard error is also indicated. Relative b-gal a
f each panel. The results are representative of two experiments for C
6 INDRACCD4S construct in this cell line was reduced by 95%,
compared to the standard LBSN vector (Fig. 3C). A
t
mmarked reduction in b-gal activity (56 and 68%) was also
bserved in the nonlymphoid cell lines, NIH-3T3 and
SA-E1, respectively, transduced with the LBSN-CD4S,
ompared to figures obtained with the wild-type vector
Figs. 3A and 3D). These findings resemble previous data
n CD4 silencer activity obtained after transient trans-
ections of murine hematopoietic cell lines (Sawada et
l., 1994). To extend the functional studies regarding the
ctivity of this inhibitory sequence, which has been only
artially investigated to date, we transduced some hu-
an tumor cell lines, including cervical-carcinoma-de-
ived HeLa and bladder-carcinoma-derived EJ cells. In
hree independent experiments, transduction of these
uman cell lines with the LBSN-CD4S vector yielded
evels of b-gal activity that were strongly reduced (range,
0–93%) compared to LBSN-transduced controls (data
ot shown); thus, the murine silencer was also functional
n human cells. This suggests that the still poorly char-
cterized factors that interact in the mouse cell with the
D4 silencer might be conserved in humans as well.
nterestingly, the recent identification of a human CD4
ilencer, showing 77% identity with the murine sequence,
ndirectly supports the hypothesis that a similar regula-
ell lines. Murine fibroblastic NIH-3T3 (A), CD41 EL-4 (B), CD81 CTLL-2
ted retroviral vectors and selected in G418-containing medium for 2–3
erials and Methods. The activity of the different constructs is expressed
bar represents the mean vector-derived b-gal activity (total activity 2
of the different vectors, compared to LBSN, are shown at the bottom
three for EL-4, and five for NIH-3T3 and TSA-E1 cell lines.
ET AL.cted c
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COLOion of CD4 gene expression might occur in humans and
ice (Donda et al., 1996). Based on these findings, we
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equately discriminate between CD41 and CD81 cells
and that the degree of suppression of gene expression is
only partial in most of the other cell lines tested. Future
work might entail juxtaposing the cellular silencer with a
cellular promoter, as well as validation of this transcrip-
tional targeting approach by generation of retroviral vec-
tors carrying other cellular silencers with a marked turn-
off potential for many cell types, such as the neuron-
restrictive silencer element (Schoenherr et al., 1996),
which should lead to expression of the transgene selec-
tively in neuronal cells.
Confirmation of silencer activity by enhanced green
fluorescent protein (EGFP)-gene transfer
To analyze in greater detail silencer activity in short-
term experiments and in the absence of drug selection,
we cloned this element in the XbaI site of the 39 LTR of
a retroviral vector expressing the EGFP marker gene
(see Fig. 1) and used it to transduce several human and
murine cell lines; thus, the activity of a given promoter
could be determined by cytofluorimetric analysis as the
percentage of EGFP1 cells, as well as by measuring the
median fluorescence intensity (MFI). Transduction exper-
iments were performed as detailed above with vectors
carrying the b-gal gene. Seventy-two hours after infec-
tion, EGFP-expressing vector-transduced cells were an-
alyzed on an Elite cytofluorometer (Coulter). NIH-3T3
cells transduced by the LESN-CD4S vector expressed
EGFP at similar percentages (70.4% vs 72.7%) but much
lower MFI (665 vs 781), compared to NIH-3T3 cells trans-
duced by the LESN vector carrying wild-type LTRs. In
these same experiments, we also evaluated the activity
of a retroviral vector that carries the silencer element in
the same position but in the opposite orientation, termed
LESN-CD4Sa. Interestingly, this construct yielded an
GFP expression pattern in NIH-3T3 cells similar to that
f the LESN vector (83.1% EGFP1 cells, MFI 5 782), thus
ndicating that CD4 silencer function might be orienta-
ion-dependent, at least in the context of retroviral vec-
ors; this also shows that the modulation of LTR activity in
D81 cells is silencer-dependent, rather then induced by
pacer effects caused by the separation of the viral
romoter and enhancer by silencer insertion. Titration
xperiments indicated that the LESN, LESN-CD4S, and
ESN-CD4Sa retroviral vectors yielded similar amounts
f virus, on average 4.4 6 0.4 3 105, 4.2 6 0.5 3 105, and
4.8 6 0.5 3 105 TU/ml, respectively; this was also con-
irmed by G418 selection of transduced NIH-3T3 cells
data not shown).
We then used these vectors to transduce lymphoid cell
ines, including the CD41CD81 JM and the CD41 Jurkat
cell lines. In preliminary experiments, we found that
CD4 SILENCER ACTIVITVSV-G pseudotyped MLV particles transduced these cell
lines more efficiently than particles displaying the A-MLVEnv (data not shown), and they were therefore used in
the following experiments. The same cell lines trans-
duced with the LXSN retroviral vector, not carrying EGFP,
served as the negative control for EGFP-expression anal-
ysis. Gene transfer in JM cells revealed that the silencer-
carrying vector expressed EGFP at much lower levels
than the standard vector; 22.2% of JM cells expressed
EGFP after transduction with LESN-CD4S, with MFI 5
22, versus 55.7% of EGFP1 JM cells (MFI 5 524) with
the LESN vector (Fig. 4A and 4B). Virus titration on
NIH-3T3 cells confirmed that similar amounts of vector
virus were present in the two preparations (4 3 105 and
.8 3 105 TU/ml, respectively), indicating that these find-
ings cannot be attributed to differences in titer. The
reduced activity of CD4 silencer-carrying vector in JM
cells is in agreement with previous findings in transgenic
mice generated with different constructs carrying the
CD4 silencer, indicating a lack of expression of the
marker gene in CD41CD81 thymocytes (Duncan et al.,
1996). In the CD41 Jurkat lymphoid cell line, however, the
LESN-CD4S construct expressed EGFP at levels similar
to those generated by the standard LTR vector; 71.8%
(MFI 5 466) and 75.6% (MFI 5 419) EGFP1 Jurkat cells
ere detected following transduction by LESN (Fig. 4C)
nd LESN-CD4S (Fig. 4D), respectively. Similar figures
ere found following transduction of CD41 Molt-3 cells
with these vectors (data not shown). These findings dem-
onstrate that the silencer-carrying vector provides effi-
cient EGFP expression in CD41 cell lines, but shows
impaired expression in fibroblastic and CD81 lymphoid
ell lines, compared to the vector carrying wild-type LTRs
n the absence of drug selection, thus confirming and
alidating those already obtained with the b-gal gene. In
vitro culture of these transduced cells up to 8 weeks
indicated that EGFP marker expression by both the wild-
type and the CD4 silencer-carrying retroviral vector was
stable (data not shown).
Application to clinically relevant targets: Transduction
of human primary lymphocytes with the CD4
silencer-carrying retroviral vector
Having established the activity of the LESN-CD4S vec-
tor in cell lines, it was important to verify whether the
observed suppression of reporter gene activity might
also be detected in primary CD81 lymphoid cells. As we
ad already shown that the murine silencer is also active
n human cells, we transduced the relevant vector into
rimary human lymphocytes. We first compared infectiv-
ty for peripheral blood mononuclear cells (PBMC) of
o-MLV particles displaying the A-MLV, VSV-G, or Gib-
on ape leukemia virus (GaLV) envelopes and found the
est results, in terms of the percentage of EGFP1 lym-
phocytes, using the GaLV Env pseudotyped particles
87RETROVIRAL VECTORS(data not shown). Therefore, we used MLV/GaLV
pseudotypes to transduce human primary lymphocytes
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e profiin all subsequent experiments. Freshly isolated human
lymphocytes were transduced by cocultivation with a
PG13-derived packaging cell line (Miller et al., 1991). One
representative experiment is shown in Fig. 5, while the
results of six independent transductions of PBMC from
healthy donors are summarized in Table 1. Overall, fol-
lowing transduction with the wild-type LESN vector, we
found that EGFP was expressed at slightly higher levels
in CD81 than CD41 T cells, in terms of both percentage
of EGFP1 cells and MFI (Fig. 5 and Table 1); however,
ollowing gene transfer with the LESN-CD4S vector, a
ignificant decrease in EGFP expression in CD81 cells,
compared to CD41 T cells, was observed (Fig. 5 and
Table 1) (P 5 0.02, Wilcoxon paired t test). Thus, the
ector carrying the CD4 silencer did not differ signifi-
antly from the wild-type retroviral vector in its capacity
o express the transgene in the CD41 lymphocyte subset,
but it showed greatly impaired activity in CD81 cells.
hese findings indicate that the LESN-CD4S vector can
FIG. 4. Transduction of human lymphoid cell lines by different MLV/V
were infected with either LESN or LESN-CD4S retroviral vectors g
transduction the percentage of EGFP-expressing cells was quantified
construct and the median fluorescence intensity (MFI) are indicated. Th
88 INDRAClso be exploited to express genes of interest preferen-
ially in human primary CD41 T lymphocytes.
c
sThe generation of hybrid LTRs, carrying either cellular
regulatory elements or heterologous viral enhancers, is
an established procedure aimed at modulating the tran-
scriptional activity of retroviral vectors (Couture et al.,
1994; Fassati et al., 1998; Robinson et al., 1995; Saller et
l., 1998; Vile et al., 1995); the inclusion of a cellular
ilencer, however, is a novel approach that constitutes
n alternative to the utilization of cellular promoters or
nhancers for tissue-specific expression. Many workers
ave found that inclusion of cellular regulatory se-
uences in retroviral vectors is not always a successful
rocedure, because the functional properties of many
romoters are lost or deregulated in the retroviral setting
Gunzburg and Salmons, 1996; Malik et al., 1995; Miller
nd Whelan, 1997; Moore et al., 1991); our findings with
etroviral vectors carrying the human CD4 promoter and
he murine proximal enhancer also indicated as much.
n the other hand, this is not completely surprising in
iew of the fact that the physiological expression of many
etroviral vectors carrying EGFP as a marker gene. JM and Jurkat cells
d by transient transfection of 293T cells. Seventy-two hours after
CS analysis. The mean percentage of EGFP-positive cells for each
le of the mock-transduced lymphoid cells in each panel is also shown.
ET AL.SV-G r
enerate
COLOellular genes is regulated by multiple sequences, often
cattered throughout many kilobases of genomic DNA,
o y (MFI)rather than by the promoter alone. Unfortunately, size
constraints physically limit the inclusion of larger regu-
latory sequences in the vectors. Our findings suggest
that it might be feasible to modify the function of the viral
LTR, a highly complex transcriptional machinery, by add-
ing a small inhibitory sequence that will repress tran-
scription in defined cell types. In keeping with the results
of Ferrari et al., who inserted a muscle-specific enhancer
into the same XbaI site of a similar retroviral vector
(Ferrari et al., 1995), the insertion of the 438-bp-long
silencer into the U3 region of the viral LTR was well
tolerated in that it induced neither genomic instability nor
a decrease in virus titer. In conclusion, we suggest that
the exploitation of cellular silencers in retroviral vectors
might contribute to generate transcriptionally targeted
vectors; this modification of the MLV vectors could
be of general interest because it might be applied to
FIG. 5. Transduction of human primary T lymphocytes with differen
PBMC were infected by cocultivation on PG13 packaging cells releasin
PBMC were labeled with either anti-CD4 or anti-CD8 and the percentag
diagrams show either CD41EGFP1 or CD81EGFP1 cells (upper right of
f EGFP-positive lymphoid cells, and the median fluorescence intensit
CD4 SILENCER ACTIVITother vector systems, including adenoviral and lentiviral
vectors.MATERIALS AND METHODS
Plasmids
The human CD4 promoter and the murine CD4 proxi-
mal enhancer and silencer were amplified from genomic
DNA by PCR using the following primers:
CD4P-for: 59-ATA CCG CGG-ACT TCC TGG GCT CAA
GCA ATC CTC-39;
CD4P-rev: 59-GCG GCG ACG CGT-AGA CAG GAA GCC
CGA TGG CAA G-39;
CD4E-for: 59-TCC CCG CGG-AAA TTT GAG CCC CAG
CTG TTA GCC-39;
CD4E-rev: 59-TCC CCG CGG-CAA TCT ACC TCC ACC
CTG GCT GTC-39;
CD4S-for: 59-ATA CCG CGG-GCT CCC ACC CAC TGC
CAC CCA-39
iral vectors carrying EGFP as a reporter gene. PHA-activated human
r LESN or LESN-CD4S vectors. Seventy-two hours after transduction,
FP-expressing lymphoid cells was quantified by FACS analysis. FACS
igure). The individual constructs used for transduction, the percentage
are indicated.
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ACT CAA CAC C-39.
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COLOPCR was performed in 50 ml of standard buffer contain-
ing 0.2 mM of each primer and 1 U of Taq polymerase
(Perkin–Elmer) under the following conditions: 94°C de-
naturation, 1 min; 65°C annealing, 30 s; 72°C extension,
1 min; for 35 cycles, with 1 mg of genomic DNA as
emplate. Procon-CD4P was constructed by digesting
he 1083-bp PCR fragment containing the human CD4
romoter with MluI/SacII restriction enzymes and cloning
nto the 39 LTR of a promoter conversion vector at the
orresponding unique sites (Fig. 1). Details of procon
onstruction and characterization are reported else-
here (Mrochen et al., 1997; Saller et al., 1998). Procon-
D4P 1 E was then generated by inserting the SacII-
igested 373-bp PCR fragment into procon-CD4P at the
acII site (Fig. 1). Finally, LBSN-CD4S was constructed
y blunt-end cloning of the 438-bp murine CD4 silencer
n the XbaI site of the LBSN vector (Fig. 1). This XbaI site,
ositioned at bp 3186 of the parental LXSN retroviral
ector genome (Miller and Rosman, 1989), from which
BSN derives, is placed between the Mo-MLV enhancer
nd promoter elements (Fig. 1). For EGFP experiments,
he murine CD4 silencer was cloned by the same pro-
edure used in the LESN vector (Fig. 1), which is a
erivative of LXSN carrying the gene for an enhanced
reen fluorescent protein driven by the Mo-MLV LTR
Klein et al., 1997). All constructs were verified by se-
uencing before functional assays were performed.
The Mo-MLV Gag-Pol expression construct gag-polgpt
arbors the Mo-MLV gag and pol genes under the con-
rol of the Mo-MLV long terminal repeat and a SV40
olyadenylation signal (Markowitz et al., 1988). The con-
truct lacks c packaging sequences as a consequence
TABLE 1
EGFP Expression in LESN and LESN-CD4S Transduced
Human Lymphocytesa
Subject No.
% EGFP1 cells (MFI)
LESN LESN-CD4S
CD4 CD8 CD4 CD8
1 11.5 (454) 14.5 (501) 8.4 (470) 3.4 (413)
2 16.6 (406) 16.7 (438) 16.3 (443) 15.5 (354)
3 20.6 (484) 23.5 (529) 23.1 (414) 13.0 (382)
4 3.8 (524) 5.9 (640) 2.9 (475) 1.9 (474)
5 5.9 (482) 9.1 (596) 7.5 (423) 6.1 (416)
6 7.1 (549) 9.8 (569) 6.0 (427) 3.4 (418)
Mean 6 SD 10.9 6 6.6
(483 6 51)
13.2 6 6.3
(545 6 72)
10.7 6 7.5
(442 6 25)
7.2 6 5.6
(409 6 40)
a Human PBMC from six healthy donors were transduced with either
ESN or LESN-CD4S retroviral vectors and analyzed 72 h after trans-
uction for EGFP expression by FACS. The percentage of EGFP-posi-
ive cells for each construct and the median fluorescence intensity
MFI) in the CD41 and CD81 subsets are indicated.
90 INDRACof a 134-base-pair deletion between the Mo-MLV LTR
and the gag gene. The amphotropic Mo-MLV Env expres-
t
wion construct SV-A-MLV env has the A-MLV env gene
nserted between Mo-MLV LTR sequences and a SV40
olyadenylation signal (Page et al., 1990). A plasmid,
amed HCMV-G, expressing the envelope protein G of
esicular stomatitis virus (VSV-G) under the transcrip-
ional control of the CMV promoter was used in one set
f experiments to pseudotype MLV particles (Yee et al.,
994) and transduce T lymphoid cell lines.
ell culture and transfections
293T human kidney cells were obtained by ATCC and
sed as a packaging cell line (Pear et al., 1993). The day
efore transfection, 1.5 3 106 293T cells were seeded in
25-cm2 tissue culture flasks. The cultures were trans-
ected with plasmid DNA using a calcium phosphate
recipitation technique (Sambrook et al., 1989). 293T,
G13, murine fibroblastic NIH-3T3, human cervix carci-
oma HeLa, human bladder carcinoma EJ, murine mam-
ary adenocarcinoma TSA-1, and murine T lymphoma
D41 EL-4 cell lines were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum
(FCS, Gibco-BRL) and 1% L-glutamine. Murine CD81
CTLL-2, human CD41CD81 JM, CD41 Molt-3, and Jurkat
ells were grown in RPMI 1640 supplemented with 10%
CS and 1% L-glutamine. Finally, PBMC were isolated by
Ficoll–Hypaque (Pharmacia-LKB) gradient centrifugation
as described (Indraccolo et al., 1995a) and cultured for
48 h in RPMI 1640 supplemented with 10% FCS and 1%
L-glutamine in the presence of phytohemagglutinin
PHA-P, Difco), prior to retroviral vector transduction.
ransduction of cells with retroviral vectors
Infectious particles were generated by transfection of
93T cells with 3 mg of the Mo-MLV Gag-Pol expression
onstruct pgag-polgpt, along with 6 mg of procon-CD4P,
roconCD4P 1 E, LBSN, LBSN-CD4S, LESN, or LESN-
D4S as transducing vectors and 3 mg of the A-MLV env
expression construct. In one set of experiments, retrovi-
ral vector pseudotypes with VSV-G envelope protein
were generated as reported (Burns et al., 1993) and used
to transduce the EGFP gene into JM, Molt-3, and Jurkat
lymphoid cell lines. Fresh medium was added to the
cultures 12–18 h before the SN was collected and pas-
saged through 0.45-mm-pore-size filters. To assess the
bility of the virions to transduce NIH-3T3 cells, serial
ilutions of the filtered SNs were layered over NIH-3T3
arget cells that had been seeded into six-well culture
lates the day before infection at 1.5 3 105 cells per well.
Protamine sulfate (8 mg/ml) (Sigma) was added to the
ells, and the cells were kept in a total volume of 2 ml.
fter 6–9 h at 37°C, 3 ml of medium was added to dilute
he protamine sulfate; 36 h later, the cells were split 1:10
n 10-cm-diameter petri dishes, and new medium con-
ET AL.aining G418 (Gibco-BRL, 500 mg/ml active compound)
as added. Following 2 weeks of culture in G418 selec-
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Y INtive medium, the viral titer was determined as described
(Klein et al., 1997) and expressed as colony forming units
per milliliter of SN. In one set of experiments, titer was
calculated by counting EGFP-expressing cells following
transduction of NIH-3T3 cells by serial dilutions of vec-
tor-containing SN and expressed as transducing units
per milliliter.
Transduction of lymphoid cell lines was performed by
using cell-free SN. To this end, 3 ml of retroviral vector-
containing SN was incubated with 2 3 105 target cells for
–9 h at 37°C in the presence of protamine sulfate (8
mg/ml) with occasional stirring. Lymphoid cells were
then pelleted, resuspended in fresh medium, and grown
for an additional 72 h before FACS analysis or selected in
G418-containing medium prior to assessment of b-gal
xpression.
Freshly isolated human lymphocytes were transduced
y cocultivation with a PG13-derived packaging cell line
Miller et al., 1991). Briefly, 4 3 106 PBMC were layered
on irradiated (1000 rads) confluent PG13 cells, releasing
either the LESN or the LESN-CD4S retroviral vectors, in
a 60-mm petri dish and cocultivated for 48 h in complete
RPMI supplemented with PHA and 100 U/ml of recombi-
nant IL2 (EuroCetus); subsequently, PBMC were trans-
ferred to 24-well plates (Becton–Dickinson) and cultured
for an additional 72 h prior to EGFP detection.
Proviral DNA analysis
Genomic DNA was obtained from vector-transduced
293T and NIH-3T3 cells using the QIAamp tissue kit
(Qiagen), according to the manufacturer’s protocol. For
PCR analysis, in the case of LBSN and LBSN-CD4S
vectors, 0.5 mg of genomic DNA was PCR-amplified with
rimer LBSN-for (59-CAG ATC AAG GTC AGG AAC AG-39)
nd LBSN-rev (59-CCG CCA GAT ACA GAG CTA GT-39),
sing standard PCR buffer and the following conditions:
4°C denaturation, 1 min; 60°C annealing, 30 s; 72°C
xtension, 1 min; for 35 cycles. PCR products were then
un on a 1.2% agarose gel and visualized by ethidium
romide staining.
For analysis of the LESN and LESN-CD4S vectors, 10
mg of genomic DNA was digested to completion with
either KpnI or NheI restriction enzymes (New England
Biolabs), electrophoresed on 0.8% agarose gels, trans-
ferred to nylon membranes (Hybond-N, Amersham) by
Southern blotting as described (Indraccolo et al., 1995b),
nd hybridized to 2 3 107 cpm of a 32P-labeled 1.2-kb
indIII/SmaI DNA probe from plasmid pSV2-neo. Filters
ere washed under high-stringency conditions and ex-
osed to autoradiography for 5–7 days at 270°C.
etermination of b-gal activity
Two to three weeks following G418 selection, pools of
CD4 SILENCER ACTIVITabout 100 clones of NIH-3T3, TSA-1, HeLa, and EJ cells,
as well as bulk cultures of lymphoid cell lines, were lysedin 100 mM potassium phosphate, pH 7.8, 0.2% Triton
X-100, and 1 mM dithiothreitol lysis buffer. The protein
concentration in the cell lysates was determined spec-
trophotometrically using the Bio-Rad Dc protein assay kit
(Bio-Rad) according to the manufacturer’s instructions,
and the samples were then analyzed in duplicate for
b-gal activity using the Galacto-Light Plus kit (Tropix) and
a plate luminometer (Packard). b-Gal activity was ex-
ressed as counts per second per microgram of protein
n the sample.
ytofluorimetric analysis
EGFP-expressing vector-transduced lymphoid cells
ere analyzed on an EPICS-Elite cytofluorimeter
Coulter). At different times after infection, cells were
elleted, washed, and fixed. PBMC were labeled with
ither anti-CD4PE or anti-CD8PE (Dako) mAbs. Two-
olor immunofluorescence was carried out as reported
Indraccolo et al., 1993) and analyzed using the PRISM
arameter of the Elite cytofluorometer; the negative con-
rol setting for each mAb was determined by using la-
eled Ig of the corresponding isotype. Mock-transduced
ell lines served as the negative control for EGFP-ex-
ression analysis. The median fluorescence intensity
as calculated by the following formula: MFI 5
og10(mean p 10) p (1024/4).
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